Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Dal Maso A, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, Cecere FL, Del Conte A, Nardo G, Buoro V, Scattolin D, Monteverdi S, Urso L, Zulato E, Frega S, Bonanno L, Indraccolo S, Calabrese F, Conte P, Pasello G. Dal Maso A, et al. Clin Lung Cancer. 2020 Jan;21(1):1-14.e3. doi: 10.1016/j.cllc.2019.07.009. Epub 2019 Aug 5. Clin Lung Cancer. 2020. PMID: 31601525
Corrigendum to "Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?" [Crit. Rev. Oncol. Hematol. 138 (June) (2019), 87-103].
Frega S, Dal Maso A, Ferro A, Bonanno L, Conte PF, Pasello G. Frega S, et al. Among authors: dal maso a. Crit Rev Oncol Hematol. 2019 Aug;140:73. doi: 10.1016/j.critrevonc.2019.05.018. Epub 2019 Jun 6. Crit Rev Oncol Hematol. 2019. PMID: 31176852 No abstract available.
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.
Frega S, Dal Maso A, Pasello G, Cuppari L, Bonanno L, Conte P, Evangelista L. Frega S, et al. Among authors: dal maso a. Cancers (Basel). 2020 May 21;12(5):1303. doi: 10.3390/cancers12051303. Cancers (Basel). 2020. PMID: 32455666 Free PMC article. Review.
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer.
Attili I, Bonanno L, Karachaliou N, Bracht JWP, Berenguer J, Codony-Servat C, Codony-Servat J, Aldeguer E, Gimenez-Capitan A, Dal Maso A, Fassan M, Chaib I, Molina-Vila MA, Passaro A, de Marinis F, Pasello G, Guarneri V, Conte PF, Rosell R. Attili I, et al. Among authors: dal maso a. Transl Lung Cancer Res. 2020 Oct;9(5):1810-1821. doi: 10.21037/tlcr-20-681. Transl Lung Cancer Res. 2020. PMID: 33209603 Free PMC article.
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Pavan A, Bragadin AB, Calvetti L, Ferro A, Zulato E, Attili I, Nardo G, Dal Maso A, Frega S, Menin AG, Fassan M, Calabrese F, Pasello G, Guarneri V, Aprile G, Conte P, Rosell R, Indraccolo S, Bonanno L. Pavan A, et al. Among authors: dal maso a. Transl Lung Cancer Res. 2021 Jan;10(1):202-220. doi: 10.21037/tlcr-20-674. Transl Lung Cancer Res. 2021. PMID: 33569305 Free PMC article.
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Dal Maso A, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte P, Pasello G. Dal Maso A, et al. Future Oncol. 2021 Jul;17(19):2513-2527. doi: 10.2217/fon-2021-0356. Epub 2021 May 14. Future Oncol. 2021. PMID: 33988036
25 results